Cite
HARVARD Citation
Pignata, S. et al. (2021). Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial. Lancet oncology. 22 (2), pp. 267-276. [Online].